New York State Teachers Retirement System (NYSTRS)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$790K Buy
+2,623
New +$791K ﹤0.01% 1348
2025
Q3
Sell
-191
Closed -$62K 1633
2025
Q2
$62K Sell
191
-1,487
-89% -$411K ﹤0.01% 1566
2025
Q1
$453K Sell
1,678
-4,158
-71% -$1.07M ﹤0.01% 1437
2024
Q4
$1.37M Buy
5,836
+553
+10% +$145K ﹤0.01% 1229
2024
Q3
$1.45M Buy
+5,283
New +$1.38M ﹤0.01% 1225

Other funds holding ALNY

New York State Teachers Retirement System (NYSTRS)'s ALNY Position: Q2 2026 in Review

New York State Teachers Retirement System (NYSTRS) opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2026: 2,623 shares worth $790K. The stake represents ﹤0.01% of the portfolio and ranks #1348 among its holdings. This is a return to the name: New York State Teachers Retirement System (NYSTRS) previously reported a position in ALNY as recently as Q2 2025.

New York State Teachers Retirement System (NYSTRS) first reported a position in ALNY in Q3 2024 and has held it in 5 quarters since. The position peaked at $1.45M in Q3 2024. 227 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • New York State Teachers Retirement System (NYSTRS) held 2,623 shares of Alnylam Pharmaceuticals worth $790K as of Q2 2026.
  • Alnylam Pharmaceuticals was a new New York State Teachers Retirement System (NYSTRS) position in Q2 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of New York State Teachers Retirement System (NYSTRS)'s portfolio in Q2 2026, its #1348 holding.
  • New York State Teachers Retirement System (NYSTRS) first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
  • New York State Teachers Retirement System (NYSTRS)'s Alnylam Pharmaceuticals position peaked at $1.45M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on New York State Teachers Retirement System (NYSTRS)'s 13F filing for Q2 2026, filed 23 Jul 2026.